Both exercise (EIB) and mannitol challenges were performed in asthmatic patients to assess and compare their pulmonary gas exchange responses for an equivalent degree of bronchoconstriction.
INTRODUCTION
Exercise-induced bronchoconstriction (EIB), often an indication that asthma is not properly controlled (3) , is triggered by dehydration and an increased osmolarity of the airway surface as a consequence of evaporative water loss in conditioning the inspired air (1) . The airways of asthmatics with EIB are also responsive to hyperosmolar aerosols (4; 9; 18; 30) and both exercise and inhalation of mannitol provoke release of the same inflammatory mediators (5; 7).
They are both used to identify bronchial hyperresponsiveness in individuals suspected of having asthma (6; 29) . The possible advantage of comparing mannitol to exercise and other osmotic stimuli is that the sensitivity to mannitol correlates very well with the reactivity to exercise (9) . It also correlates with hypertonic saline response (PD 20 ) (6) and its ease of administration, without any known serious adverse effect, now facilitates its use as a surrogate for EIB in laboratories.
Further EIB has a high prevalence in athletes and the effects on pulmonary gas exchange are of particular interest to those performing at the elite level.
Previous studies on EIB pathophysiology showed a distinctive ventilation-perfusion (V A /Q) response (13; 35) compared to all direct and indirect pharmacological challenge tests in asthma (11; 19; 20; 27) . V A /Q imbalance (35) during EIB has previously been demonstrated in a limited group of adults and there is one study in children revealing regions of high V A /Q ratio alone, possibly related to increased alveolar pressures thereby reducing blood flow in these areas (13) .
Our aim was to study the pulmonary gas exchange response to EIB in mild asthmatics and compare this with the response to mannitol-induced bronchoconstriction in the same subjects. We proposed that the interaction between intrapulmonary (i.e., V A /Q mismatch) and extra-pulmonary 
METHODS

Subjects:
Eleven non-smoking subjects with EIB (27±4 yrs; FEV 1 , 86±8%; 8 females) were recruited. For inclusion, subjects were required to have symptoms of asthma in the last year, an FEV 1 B 70% predicted and 1.5 L and a decrease in FEV 1 of B 20% from baseline after a standardized EIB challenge breathing dry air. The time of maximum fall in FEV 1 on the screening EIB challenge was recorded for use in the subsequent exercise tests. Subjects with an exacerbation of asthma and/or a respiratory infection within the preceding 6 weeks were excluded, as were those treated with oral or inhaled glucocorticosteroids, leukotriene-receptor antagonists or chromones within the preceding 3 months. Maintenance therapy, antihistamines (1 patient), long-acting ß 2 -agonists (1 patient) or rescue short-acting ß 2 -agonists (11 subjects), was withheld for at least 72, 48 and 12 h, respectively. For each visit, subjects were asked to refrain from heavy exercise and consumption of caffeine/tea-containing beverages/foods for at least 12 h before arrival in the laboratory. The study was approved by the Ethics Review Board at Hospital Clínic (Protocol # 2312-2004) and all subjects gave written informed consent.
Study Design. A two-period sequential study design was used. All subjects visited the laboratory on 3 separate occasions. At visit 1 (screening) visit, clinical evaluation, spirometry, and EIB challenge (23) were carried out. Subjects fulfilling the inclusion criteria were scheduled for two additional visits for invasive measurements before and after challenge with exercise (visit 2) and inhaled mannitol (visit 3) challenges, one week apart. The sequence of the challenges was intentional in order to match the severity of bronchoconstriction for exercise and mannitol. At both visits 2 and 3, a radial artery catheter and a central (superior cava vein) catheter placed The subjects were asked to inhale from the device from near to functional residual capacity to near to total lung capacity and to hold their breath for 5 s. Subjects were encouraged to keep a nose clip on for 10 s after inhalation and then exhale through their mouth to minimize deposition of the particles in the nasopharynx. Two acceptable FEV 1 measurements were obtained and the highest value was used for the analysis. Pre-challenge baseline FEV 1 was used to calculate the maximum % fall in FEV 1 after mannitol. In addition the dose of mannitol that induced a fall of 15% below baseline (PD 15 ) was determined as a measure of sensitivity.
Measurements.
At baseline and at 5, 15 and 45 min after challenge, subjects breathed quietly through a mouthpiece connected to a non-re-breathing two-way valve with a low dead space Likewise, V E and respiratory rate (f) were measured using a calibrated Wright Respirameter (MK8, BOC-Medical, Essex, UK). The alveolar-arterial oxygen partial pressure difference (AaPO 2 ) was calculated according to the alveolar gas equation using the measured RER. MIGET was used to estimate the distribution of V A /Q ratios without sampling mixed venous inert gases (26) . Using this method, Q T needs to be measured directly. The dye dilution technique (DC-410;
Waters Instruments Inc, Rochester, MN) using a bolus of 5 mg of indocyanine green injected through the central vein catheter was used to measure Q T (28) .
Mixed venous inert gas concentrations were computed from mass balance equations (26) . Using the measured solubilities for the six gases from each subject, and their concentrations in arterial blood and expired breath, inert gas gradient indexes (i.e.,
retentions [R] minus excretions [E*]
corrected for acetone) were plotted against the solubility for each gas to obtain retention-solubility curves (14; 26) . In addition, the dispersions of pulmonary blood flow (Log SDQ) and of alveolar ventilation (Log SDV) (normal values O0.60 to 0.65) (10) and an overall index of V A /Q heterogeneity (DISP R-E*) (the root of the mean square difference among measured retentions was derived by linear interpolation from the cumulative dose on log-transformed data and the geometric mean was calculated for the group. Differences at baseline, before exercise and/mannitol challenges, were assessed using paired t-test. The effects of each challenge on functional and gas exchange variables were assessed by a repeated measures analysis of variance (ANOVA) followed by Bonferroni's t test post hoc to determine statistical differences.
Comparisons between the effects of exercise and mannitol challenges were assessed by two-way repeated measures ANOVA. Whenever a significant interaction between challenges over time was observed, differences at each time point were analyzed with a post-hoc paired t-test.
Correlations among variables were established by calculating Pearson's correlation coefficients.
Statistical analysis was performed with specialized computer software (SPSS 12.0, Inc, Chicago, IL, USA) and significance was set at p<0.05 values in all instances. Arterial blood gases were normal in all subjects, while V A /Q distributions were normal (i.e., narrowly unimodal) in eight and slightly broader than normal in three. In spite that inert gas gradients (R-E*) for the five gases for both EIB and mannitol (SF 6 . This exercise provoked a 37±16% fall in FEV 1 (p<0.01) at 3.6±1.6 min after ceasing exercise (maximal fall). Five min after the maximal response, the fall in FEV 1 remained almost unchanged (Table 1) while Rrs increased (by 121±71%)(p<0.01 each).
Mean IC decreased at 5 and 15 min (Table 1) . Likewise, V E (by 123±60%), Q T (by 48±29%), VO 2 (by 54±25%) and HR increased at 5 and 15 min (p<0.01 each) and respiratory frequency (f) (Figure 3) . At five min, five subjects developed broadly unimodal V A /Q patterns alike during EIB and six a bimodal alveolar ventilation profile (five of these subjects also showed it during EIB) ( Figure 1) ; at 90 min, all measurements had returned to baseline (±5%). No correlations were shown between gas exchange and spirometric indices.
Comparison between EIB and Mannitol. The reactivity to exercise (maximal FEV 1 fall at the screening visit) was related to the sensitivity (expressed as PD 15 ) to mannitol (r= U0.86; p=0.001).
Maximal changes in FEV 1 , Rrs and IC were not different. As expected, at 5 min, V E , Q T and VO 2 were higher after EIB than after mannitol (Table 1, Figure 2 ), whereas at 45 min all these values were comparable to baseline for both challenges. At 5 min, EIB was associated with a higher PaO 2 (p<0.05), Log SDQ (p<0.01) and DISP R-E* (p<0.05) and a lower PaCO 2 (p<0.001), without differences in AaPO 2 , compared with mannitol. By contrast, Log SDV was similarly altered during EIB and mannitol (Table 2, Figure 2) . No correlation was shown between pulmonary perfusion and alveolar ventilation dispersions. As for inert gas gradients (R-E*) (Figure 3 ). FEV 1 , Rrs, PaO 2 and AaPO 2 remained abnormal at 60 min.
Based on the modeling approach (Figure 4) , an increase of 105% in V E caused an increase in PaO 2 , 5 min after EIB of the order of 29.2 mmHg, whereas increasing Q T by 32%, favored an increase in PaO 2 of 3.7 mmHg and increasing VO 2 by 37% reduced PaO 2 by 18 mmHg. When all factors were combined together, the result was a gain in the modeled PaO 2 of 16.9 mmHg. Accordingly, the difference between the predicted PaO 2 according to MIGET at 5 min during EIB (17.8 mmHg) and the net change in PaO 2 estimated using this modeling was just of the order of 0.9 mmHg (changing V E , Q T and VO 2 to mannitol levels). This finding indicates therefore that altogether these three factors played a key role in modulating the PaO 2 differences between the two challenges, although the increases in both V E and Q T were overall more influential. Before discussing these findings, two methodological limitations of the study should be acknowledged. First, general experimental limitations of MIGET have been discussed at length in previous papers (12; 26; 32) . With MIGET many experimental challenge situations have been investigated repeatedly (11; 20; 35) such that MIGET should be a more than reasonable approach to assess the pulmonary gas exchange status during both challenges. One established facet of the MIGET is that there is an association between the Log SD indexes and the RSS. If a given, initially error-free set of retentions is perturbed with progressively increasing amounts of random error and the data submitted to the inert computer gas analysis, the recovered values of Log SD indexes will be smaller the greater the errors, and the RSS will become obviously larger (12) . The RSS is considered to be the best descriptor of the quality of MIGET and our results exhibited low values, thus reflecting very good quality data. From a pathophysiologic viewpoint, all V A /Q data were internally consistent and fitted quite well with the overall functional time course exhibited by our participants. Second, we did not measure actual temperatures during exercise. Instead, we corrected arterial blood gas data at the standard body temperature to the expected increases in PaO 2 and decreases in AaPO 2 according to the achieved metabolic demands during exercise (i.e., VO 2 ) (17). We consider that these temperature corrections were sufficiently reliable to modify the arterial blood gases to their actual values.
Gas Exchange Responses to EIB and Mannitol
The study was primarily designed to compare the pulmonary gas exchange responses to EIB and mannitol as both are used as bronchoprovocation tests. We used mannitol therefore as a comparator for its clinical usefulness in diagnosing EIB and its correlation with EIB reactivity. As expected, maximum bronchoconstriction occurred within a few minutes after the cessation of exercise when V E , Q T and VO 2 were still considerably increased above baseline. The bronchoconstrictive effects of EIB on pulmonary gas exchange were characterized by moderate V A /Q disturbances (i.e., increased inert gas gradients for halothane, ether and acetone and increases in Log SDQ and Log SDV). As shown by the modeling, the higher V E and Q T after exercise almost certainly improved alveolar and mixed venous PO 2 , respectively, likely contributing to a less marked hypoxemia than might be expected (16; 33) although the simultaneous increased VO 2 exerted significant counterbalance and contributed to the underlying levels of hypoxemia. From a gas exchange viewpoint, an increased Log SDQ even in the absence of a bimodal pattern, reflecting the presence of regions of low V A /Q ratio (26) At 5 min, IC decreased suggesting gas trapping, a finding akin to increased Log SDQ previously observed in both adults and children (13; 35) . However, the contention of pulmonary vasoconstriction, which may cause the abnormal Log SDV residually shown at 45 min when IC had already returned to baseline, cannot be overlooked. Urinary PGD 2 and cystLTs levels, known to be active pulmonary vasoconstrictors (2; 11), are increased in asthmatics after EIB (21) and mannitol (8) . This sustained unique increased Log SDV during mannitol and EIB challenges indicates that this effect may be related to osmotic challenges.
Interestingly, in terms of increased Log SDQ, the bronchoconstriction provoked by mannitol resulted in less V A /Q imbalance but more hypoxemia than EIB in the face of discrete increases in Q T and VO 2 . However, the increased AaPO2 was similar 5 and 15 min after both stimuli. This similarity is possible and consistent with our modeling because the marked hyperventilation during EIB increased alveolar PO2, an effect not present during the bronchoconstriction provoked by mannitol.
Comparison with other Bronchial Stimuli
Both EIB-and mannitol-induced V A /Q inequalities were, in terms of increased Log SDQ and hypoxemia, similar to those occurring following other direct and indirect provocative agents, such as methacholine (20) , histamine, LTD 4 (11), PAF , adenosine 5'-monophosphate (AMP) (20) and allergens (19) (mean Log SDQ range, 0.71-0.85) at comparable degrees of bronchoprovocation.
Notwithstanding, at variance with all the abovementioned agents, there was more increased Log In this study the mannitol was administered in doses sufficient to simulate the bronchoconstriction provoked by exercise, a protocol also used in studies to investigating the inflammatory mediators associated with mannitol-induced bronchoconstriction (7; 8) . The present study demonstrates that when the bronchoconstriction provoked by mannitol is equivalent to moderate to severe EIB there is a similar degree of pulmonary gas exchange disturbances. It is of note, however, that the two challenges did exhibit slightly different responses in terms of arterial hypoxemia, showing that there are inherent pathophysiologic differences between the two challenges.
Mannitol has recently received regulatory approval as a bronchial provocation test to identify BHR and the required target fall in FEV 1 below the baseline value required for a positive test result is 15%, a value usually associated with a mean maximum fall in FEV 1 to 21% over the next 5 min (6). This is a much lower degree of bronchoconstriction than we used to simulate the moderate to severe EIB in our subjects, and has not been associated with a significant arterial deoxygenation as measured by pulse oximetry (6) .
Conclusions
This study demonstrates that, for an equivalent degree of bronchoconstriction induced by both provoking stimuli, V A /Q imbalance during EIB is associated with less arterial hypoxemia than during mannitol-induced bronchoconstriction. This is due to the influential roles of increased V E and Q T governing PaO 2 . These V A /Q inequalities resulted from predominant widespread uneven SDA has received an educational grant from Pharmaxis via her hospital; SDA owns stocks in excess of 30,000 Euros in Pharmaxis that she purchased herself; she does not hold any stock options. She acts as a consultant to Pharmaxis in her capacity as an employee of Sydney South West Area Service who owns the intellectual property rights relating to the application for mannitol.
RRR has participated as a lecturer and speaker in scientific meetings under the sponsorship of Almirall and Chiesi; serves on advisory boards for Chiesi and Novartis; and has received laboratory research support from Esteve. 
